2018 Diabetic Gastroparesis Drug Development- Pipeline Analysis Report

May 2018 | | ID: 2F5024FA186EN
VPAResearch

Abstracts

With an estimated 3-5 million people in the US suffering from gastroparesis, with young population around 34 years being more susceptible, the Diabetic Gastroparesis presents significant market opportunities of around $5 billion to $6 billion. Metoclopramide is the only FDA approved drug for treatment of the disease and acoordingly, several researchers are focusing on developing new treatment options for the disease. Diabetic Gastroparesis is a GI disorder in which the stomach takes longer periods for emptying the contents.

Around 15 companies and universities are focusing on developing treatment options for Diabetic gastroparesis.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Diabetic gastroparesis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Diabetic gastroparesis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Diabetic gastroparesis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 DIABETIC GASTROPARESIS PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Diabetic Gastroparesis Pipeline Snapshot
2.3 Diabetic Gastroparesis Pipeline by Phase
2.4 Diabetic Gastroparesis Pipeline by Company
2.5 Diabetic Gastroparesis Pipeline by Mechanism of Action

3 DIABETIC GASTROPARESIS- COMPANY WISE PIPELINE ANALYSIS

Allergan
EndoLogic
ETX Pharma
Evoke Pharma
Shire-Movetis
Takeda Pharmaceutical
Theravance Biopharma

4 DIABETIC GASTROPARESIS R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN DIABETIC GASTROPARESIS PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Diabetic Gastroparesis Pipeline by Phase, H1- 2018
Figure 2: Diabetic Gastroparesis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Diabetic Gastroparesis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

Table 1: Diabetic Gastroparesis Pipeline by Phase, H1- 2018
Table 2: Diabetic Gastroparesis Pipeline by Companies, H1- 2018
Table 3: Diabetic Gastroparesis Pipeline by Mechanism of Action, H1- 2018
Table 4: Allergan Diabetic Gastroparesis Pipeline, May 2018
Table 5: EndoLogic Diabetic Gastroparesis Pipeline, May 2018
Table 6: ETX Pharma Diabetic Gastroparesis Pipeline, May 2018
Table 7: ETX Pharma Diabetic Gastroparesis Pipeline, May 2018
Table 8: Evoke Pharma Diabetic Gastroparesis Pipeline, May 2018
Table 9: Shire-Movetis Diabetic Gastroparesis Pipeline, May 2018
Table 10: Takeda Pharmaceutical Diabetic Gastroparesis Pipeline, May 2018